1.	Prevention of CHOP-induced Chronic Cardiotoxicity Phase: Phase IV Type: Supportive care, Treatment Status: Completed Age: 15 to 70 Sponsor: Other Protocol IDs: OLSG-0401, NCT00162955
2.	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XRP6976J_4001, NCT00280098
3.	LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Phase: Phase IV Type: Treatment Status: Completed Age: 18 to 70 Sponsor: Other Protocol IDs: 2006-003750-23, LINFOTARGAM, NCT00466258
4.	PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Phase: Phase IV Type: Treatment Status: Completed Age: 15 and over Sponsor: Other Protocol IDs: LAL-RI/96, NCT00494897
5.	LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Phase: Phase IV Type: Treatment Status: Completed Age: 65 and under Sponsor: Other Protocol IDs: LAL-Ph-2000, NCT00526305
6.	Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: TaCyDexVMP7, NCT00652041
7.	Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Phase: Phase IV Type: Treatment Status: Completed Age: 18 to 75 Sponsor: Other Protocol IDs: CHOP-Z, NCT01418430
8.	Phase II/III Pilot Treatment of Pediatric Non-B, Non-T ALL in First Marrow Relapse (SIMAL #8): Intensive Re-Induction and Reconsolidation Chemotherapy with Subsequent Myeloablative Chemoradiotherapy and Rescue with Either Allogeneic or In Vitro-Purged Autologous Marrow (Summary Last Modified 11/97) Phase: Phase III, Phase II Type: Treatment Status: Completed Age: under 21 at relapse Sponsor: NCI Protocol IDs: POG-9410, POG-SIMAL-8
9.	Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SUGEN-SU101.035, CDR0000067275, SUGEN-990711, NCT00004071
10.	Phase II-III Chemotherapy with BLEO/DTIC/VBL/ADR/PRED or NM/VCR/PCB/PRED Plus Radiotherapy for Advanced Hodgkin's Disease Phase: Phase III, Phase II Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: DFCI-75100
11.	Phase II-III VCR/PRED/L-ASP Induction, CNS Therapy plus MTX vs 6-MP/MTX vs 6-MP/MTX/CTX vs 6-MP/MTX/CTX/ARA-C for Pediatric ALL Phase: Phase III, Phase II Type: Treatment Status: Closed Age: under 18 Sponsor: Protocol IDs: SJCRH-ALL-TT-8
12.	Phase II/III Chemotherapy and Hormone Therapy with ADR/VCR/DBD/PRED Followed by TMX/FXM/BLEO/HMM/MTX-CF for Metastatic Stage III/IV or Recurrent Breast Carcinoma Phase: Phase III, Phase II Type: Treatment Status: Closed Age: under 65 Sponsor: Protocol IDs: WCCC-CO-7711R, NCI-D80-048-183
13.	Phase II/III Pilot Combination Chemotherapy and Radiotherapy for Previously Untreated Childhood ALL with Poor Prognosis Phase: Phase III, Phase II Type: Treatment Status: Completed Age: under 21 Sponsor: NCI Protocol IDs: CCG-192P
14.	Phase II/III L-PAM/PRED/VCR vs VP-16/PRED/ADR for Stage II/III Myeloma (Summary Last Modified 12/89) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 20 and over Sponsor: Protocol IDs: SAFR-CT-MM-2
15.	Phase II/III Combination Chemotherapy with VCR/PRED/ADR for Induction, VCR/PRED/ADR/L-ASP for Intensification, Cranial Irradiation plus Intrathecal MTX for CNS Prophylaxis, and POMP (PRED/VCR/MTX/6-MP) for Maintenance in Patients with ALL and AUL Phase: Phase III, Phase II Type: Treatment Status: Closed Age: no age specified Sponsor: NCI Protocol IDs: DFCI-77001, NCI-T83-1310D, T83-1310
16.	Phase II/III Randomized Study of Standard-Dose vs High-Dose MTX Followed by Induction and Continuation for Patients with ALL or AUL Phase: Phase III, Phase II Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: DFCI-81001, NCI-D82-018-0400, D82-018-0400
17.	Consolidation Hemi-Body Irradiation plus Chemotherapy with CMFP (CTX/MTX/5-FU/PRED) or CAF (CTX/ADR/5-FU) for Metastatic Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 70 and under Sponsor: NCI Protocol IDs: EST-PE-179
18.	Phase II/III Randomized Comparison of Up-Front Alternating Chemotherapy vs Up-Front Intensive 6-MP/MTX for Poor Prognosis Childhood ALL Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 1 to 20 Sponsor: NCI Protocol IDs: POG-8698
19.	Phase II/III Pilot Study of Chemotherapy Consisting of Induction with VCR/ADR/ARA-C/6-MP/PRED Followed by Consolidation with CTX/ARA-C/6-MP and Maintenance with 6-MP/ARA-C/ADR in Children with AML (Summary Last Modified 11/88) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: under 20 Sponsor: Protocol IDs: ARG-GATLA-3LMA83
20.	Phase II/III Randomized Study of MP/MTX vs DCF/MP/MTX in Patients with Relapsed T-ALL or T-NHL Who Achieve Second Remission Following Induction with PVDA (PRED/VCR/DNR/ASP) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 21 and under Sponsor: NCI Protocol IDs: POG-8862
21.	Phase II/III Pilot Study of Combination Chemotherapy for Children with ALL in Relapse after Treatment on BFM Protocols (Summary Last Modified 05/2000). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III, Phase II Type: Treatment Status: Closed Age: under 20 Sponsor: Protocol IDs: ARG-GATLA-1LLAREC90, NCI-F92-0006, NCT00002499
22.	Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 19 and over Sponsor: Other Protocol IDs: 01-002-0601, NCT00205751
23.	Rituximab+Standard CHOP vs Rituximab+bi-Weekly CHOP for Untreated Stage III/IV Low-Grade B-Cell Lymphoma (JCOG0203) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 20 to 69 Sponsor: Other Protocol IDs: JCOG0203, C000000033, NCT00147121
24.	Phase III Chemotherapy with CAFVP (CTX/ADR/5-FU/VCR/PRED) Plus Surgery or Radiotherapy for Stage III Breast Carcinoma Phase: Phase III Type: Treatment Status: Completed Age: under 75 Sponsor: NCI Protocol IDs: CLB-7784, CALGB-7784
25.	Phase III CTX/PRED Induction and Consolidation vs Radiotherapy Consolidation for Stage III or IV Nodular non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Closed Age: under 75 Sponsor: NCI Protocol IDs: EST-4477